Next Gen Diagnostics Announces New York State Department of Health’s Wadsworth Center Has Joined the NGD Cefiderocol Data Consortium for the Sequencing-Based Determination of Cefiderocol Resistance

PRESS RELEASE
Written By Casey-Drew Williams

Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based determination of bacterial susceptibility to antibiotics, and the Wadsworth Center, New York State Department of Health’s public health laboratory, today announce an agreement providing for Wadsworth to join the NGD Cefiderocol Data Consortium, as NGD develops a sequence-based diagnostic tool to help determine resistance to cefiderocol, the first novel antibiotic in 30 years, developed by the 150-year-old Japanese pharmaceutical company Shionogi.

Casey-Drew Williams
Previous

Next Gen Diagnostics Developing Automated NGS Workflow for Outbreak Detection, Antibiotic Resistance Dx
Next

Next Gen Diagnostics Announces Agreement to Develop Sequence-Based Susceptibility Determination of cefiderocol